We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · March 16, 2021

Nivolumab Plus Cabozantinib Improves Outcomes in Advanced RCC

The New England Journal of Medicine


Additional Info

The New England Journal of Medicine
Nivolumab Plus Cabozantinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
N. Engl. J. Med 2021 Mar 04;384(9)829-841, TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, VM Oyervides Juárez, JJ Hsieh, U Basso, AY Shah, C Suárez, A Hamzaj, JC Goh, C Barrios, M Richardet, C Porta, R Kowalyszyn, JP Feregrino, J Żołnierek, D Pook, ER Kessler, Y Tomita, R Mizuno, J Bedke, J Zhang, MA Maurer, B Simsek, F Ejzykowicz, GM Schwab, AB Apolo, RJ Motzer, CheckMate 9ER Investigators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading